S-1/A: Heartflow IPO Targets $290M to Advance AI-Powered CAD Diagnostics

Heartflow, Inc. files for an initial public offering of 16.67 million shares at $17.00-$18.00 to fund growth in its AI-driven coronary artery disease diagnostic platform.

Summary

• Heartflow, Inc. is offering 16,666,667 shares of common stock in its initial public offering, with an expected price range of $17.00 to $18.00 per share.
• The company expects to raise approximately $265.8 million in net proceeds, or $306.4 million if underwriters fully exercise their option to purchase additional shares.
• Proceeds will be used to repay $50.0 million (or $55.0 million) of outstanding debt under the 2024 Credit Agreement, pay $6.2 million in related fees, and fund sales, marketing, R&D, and general corporate purposes, including potential acquisitions.
• Heartflow's AI-powered platform diagnoses and manages coronary artery disease (CAD) using CCTA scans, having assessed over 400,000 patients as of March 31, 2025.
• Revenue for the year ended December 31, 2024, was $125.8 million, a 44% year-over-year increase from $87.2 million in 2023.
• Gross margin for 2024 was 75%, an 8 percentage point increase from 2023, driven by increased revenue cases and efficiency improvements from AI automation.
• Net losses were $95.7 million in 2023 and $96.4 million in 2024, with an accumulated deficit of $1.0 billion as of March 31, 2025.
• Preliminary estimated revenue for Q2 2025 is $42.9 million to $43.4 million, a 38% to 40% increase from Q2 2024, with estimated gross margin between 74.5% and 75.5%.
• The U.S. market opportunity for Heartflow FFRCT Analysis and Heartflow Plaque Analysis is estimated at approximately $5 billion, covering 3.1 million and 5.5 million eligible patients, respectively.
• Existing stockholders, directors, and executive officers will collectively own approximately 50.1% of common stock post-offering, assuming no exercise of the underwriters' option.
• New investors in this offering will experience an immediate and substantial dilution of $14.64 per share based on the midpoint IPO price of $17.50.
• The company has incurred significant net losses since inception and expects to continue incurring substantial losses in the foreseeable future.

Sentiment

Score: 7

Explanation: The company demonstrates strong revenue growth, a significant market opportunity, robust clinical evidence, and favorable reimbursement trends for its innovative AI-powered diagnostic platform. However, it continues to incur substantial net losses and faces significant competition and risks associated with AI technology and market adoption of new products. The IPO provides capital but also introduces dilution and public company costs.

Positives

• Pioneered the use of software and AI for accurate, non-invasive diagnosis and management of Coronary Artery Disease (CAD).
• Heartflow Platform has been used to assess over 400,000 patients as of March 31, 2025, including 132,000 in 2024 alone, indicating strong adoption.
• Established a competitively differentiated data set of approximately 110 million annotated CCTA images, fueling AI algorithm refinement for over a decade.
• Experienced significant revenue growth, with $125.8 million in 2024 (44% YOY growth) and $37.2 million in Q1 2025 (39% YOY growth).
• Attractive gross margin profile of 75% in 2024 and Q1 2025, expanding due to AI automation in quality control processes.
• Estimated current U.S. market opportunity for Heartflow FFRCT Analysis and Heartflow Plaque Analysis is approximately $5 billion.
• Heartflow FFRCT Analysis is supported by AHA and ACC guidelines (Class 2a, Level B) and has a dedicated Category I CPT code (effective Jan 1, 2024), with coverage for approximately 99% of covered lives in the U.S.
• Heartflow Plaque Analysis received a Category I CPT code (effective Jan 1, 2026) and is covered by all seven Medicare administrative contractors (MACs).
• Extensive clinical evidence with over 100 clinical studies and more than 130,000 patients, including large randomized controlled trials (PRECISE, FORECAST), published in over 600 peer-reviewed publications.
• Clinical trials consistently demonstrate superior accuracy, clinical utility, and economic benefits, including a 78% higher likelihood of identifying patients needing revascularization and a 69% reduction in unnecessary invasive tests (PRECISE trial).
• Heartflow RoadMap Analysis improves CCTA interpretation times by approximately 25% and reduces variability by approximately 40%, enhancing workflow efficiency.
• The platform offers a better patient experience with a single 20-minute CCTA test, lower radiation exposure compared to nuclear imaging, and definitive upfront diagnosis.
• Highly scalable, capital-efficient commercial model with Territory Sales Managers (TSMs) for new accounts and Territory Account Managers (TAMs) for increasing utilization.
• Heartflow PCI Planner is expected to launch in 2026, providing advanced visualization and clinical insights for revascularization strategies.
• The company has a strong intellectual property portfolio with approximately 586 issued patents and 103 pending patent applications globally as of December 31, 2024.

Negatives

• Incurred significant net losses since inception, totaling $95.7 million in 2023 and $96.4 million in 2024, with an accumulated deficit of $1.0 billion as of March 31, 2025.
• Revenue is currently generated almost entirely from Heartflow FFRCT Analysis, representing 99% of total revenue as of March 31, 2025, indicating high product dependency.
• Preliminary Q2 2025 gross margin is expected to decrease to 74.5%-75.5% from 76.8% in Q2 2024, primarily due to investment in hiring and training production personnel.
• Cash and cash equivalents are expected to decrease to $80.2 million by June 30, 2025, from $109.8 million on March 31, 2025, due to bonus payments and IPO-related costs.
• Operating expenses are expected to increase by 22% to 25% in Q2 2025 compared to Q2 2024.
• New investors in the IPO will experience immediate and substantial dilution of $14.64 per share.
• The company does not intend to pay dividends in the foreseeable future, meaning returns depend solely on stock price appreciation.
• The commercialization of Heartflow Plaque Analysis is nascent, with minimal revenue generated to date, and its market acceptance is uncertain.
• The company faces significant competition from traditional non-invasive tests and other AI-based platforms, which could develop more effective or cost-effective products.
• Reliance on third-party CCTA images and CT manufacturers poses a risk if formats change or manufacturers develop competing products.
• The company's credit agreement contains restrictive covenants that may limit business operations and could lead to an event of default if not met.
• A significant portion of outstanding shares (approximately 64.6 million) will be eligible for sale after lock-up periods, potentially causing stock price decline.

Risks

• Incurring significant net losses and expecting additional substantial losses in the foreseeable future, with no assurance of achieving or sustaining profitability.
• High dependence on the success of Heartflow FFRCT Analysis, which currently generates almost all revenue.
• Risk that healthcare providers may be unwilling to change their standard practice regarding CAD evaluation, hindering adoption of the Heartflow Platform.
• Inadequate or reduced third-party payor coverage and reimbursement for the Heartflow Platform, or changes in coding policies, could negatively impact adoption.
• Risks associated with a concentrated customer base, where the loss of one customer could result in a disproportionate loss across accounts.
• Significant competition in a rapidly changing technological environment, with potential for competitors to develop more effective, accurate, reliable, or cost-effective products.
• Uncertainty regarding market acceptance and utilization levels for the nascent Heartflow Plaque Analysis product and any future products.
• Risks associated with the use and development of AI models, including operational challenges, legal liability, reputational concerns, and competitive risks from incorrect design, poor data, or unforeseen bugs.
• Failure to properly manage future growth could strain personnel, IT systems, and other resources, adversely affecting the business.
• Business disruption from catastrophic events such as natural disasters, power loss, telecommunications failure, cyberattacks, or supply chain issues (e.g., contrast media shortages).
• Dependence on information technology systems, with any failure potentially harming business and operating results.
• Vulnerability to security breaches and attacks on networks and third-party service providers, leading to data compromise, system disruptions, and reputational harm.
• Extensive regulatory requirements for product market entry and maintenance, with failure to comply potentially leading to adverse regulatory actions, delays, or withdrawal of products.
• Inability to obtain and maintain sufficient intellectual property rights, or the scope of rights being too narrow, allowing third parties to commercialize similar technologies.
• Credit agreement restrictions that may limit the company's ability to operate its business, including incurring additional indebtedness, mergers, or acquisitions.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing stock price decline.
• Exposure to risks associated with currency fluctuations due to international operations.
• Limitations on the ability to use net operating losses (NOLs) and tax credits to offset future taxable income due to ownership changes (Section 382 of the Code).
• Potential for adverse tax consequences from international operations and varying effective tax rates.
• No active trading market for common stock may develop, leading to price volatility and difficulty in selling shares.
• Reduced reporting requirements as an emerging growth company could make common stock less attractive to investors.
• Increased costs and additional regulations as a public company, potentially lowering profits or making business operations more difficult.
• Failure to design, implement, and maintain effective internal control over financial reporting could lead to loss of investor confidence.
• Principal stockholders and management owning a significant percentage of stock, enabling them to exert significant control over stockholder approval matters.
• A significant portion of total outstanding shares being restricted from immediate resale, with future sales potentially causing stock price decline.
• Provisions in charter documents and Delaware law could discourage takeovers and lead to entrenchment of management.
• Broad discretion in the use of net IPO proceeds, which may not be used effectively.
• No intention to pay dividends in the foreseeable future, making investment returns dependent on stock price appreciation.
• Risk of securities litigation due to stock price volatility.

Future Outlook

Heartflow plans to continue expanding its Heartflow Platform adoption by new accounts and broadening awareness of the CCTA + Heartflow pathway to drive volume at existing accounts. The company expects to launch and drive adoption of its Heartflow Plaque Analysis product and invest in additional clinical evidence to support adoption and expand indications, including for asymptomatic patients. Further technology leadership will be pursued through continued investment in the platform, leveraging it to pursue adjacent and international markets. The next product, Heartflow PCI Planner, is expected to launch in 2026.

Management Comments

• We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (CAD).
• We believe that we are the most widely adopted AI-powered test for CAD.
• We believe the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance workflows, will continue to support our growth and advance the CCTA + Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD.
• We believe our Heartflow Platform delivers superior clinical utility and economic value to our customers and the broader healthcare system.
• We believe the continued growth of our company will primarily be driven by our differentiated approach, market leadership, attractive revenue model, large addressable market, robust clinical evidence, established reimbursement, unique AI capabilities, and experienced leadership team.

Industry Context

Cardiovascular disease, particularly CAD, remains the leading cause of death worldwide, with healthcare systems lacking scalable methods for personalized detection and diagnosis. Traditional non-invasive tests (NITs) like SPECT, echocardiography, and PET are often unreliable, leading to high false negative and false positive rates. CCTA has emerged as a preferred first-line test, but lacks quantification of CAD severity, blood flow limitations, or plaque composition. Heartflow's AI-powered platform addresses these limitations by enhancing CCTA with actionable insights, positioning the CCTA + Heartflow pathway to become the standard of care. The industry is seeing a shift towards more precise, personalized approaches to cardiovascular care, driven by AI advancements and guideline adoption.

Comparison to Industry Standards

• Heartflow FFRCT Analysis demonstrated superior diagnostic accuracy (AUC of 0.94) compared to PET (0.87), CCTA alone (0.83), and SPECT (0.70) for vessel-specific ischemia, using invasive FFR as the reference standard (PACIFIC trial).
• The PRECISE trial showed Heartflow FFRCT Analysis was 78% more likely to identify patients needing revascularization and resulted in a 69% reduction in unnecessary invasive diagnostic angiograms compared to usual care pathways (which often involved traditional NITs).
• The PLATFORM trial demonstrated that the CCTA + Heartflow FFRCT Analysis pathway reduced unnecessary invasive coronary angiography by 83% and showed a 23% reduction in costs at 90 days and a 32% reduction at one year compared to a usual care invasive pathway.
• Heartflow Plaque Analysis showed 95% agreement with invasive intravascular ultrasound (IVUS) in quantifying total coronary plaque volume (REVEALPLAQUE study), a high concordance with the invasive reference standard.
• Traditional stress-based NITs (SPECT, PET, stress echocardiography) infer heart disease based on blood perfusion, often resulting in 20-50% false negatives and up to 55% false positives, unlike Heartflow's direct measurement of disease.
• Competitors in the AI-based CCTA analysis space include earlier-stage companies such as Cleerly, Inc., Elucid Bioimaging Inc., and Keya Medical Technology Co., Ltd., which may offer competing products or on-premise solutions.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any litigation the outcome of which, if determined adversely, would individually or taken together, materially and adversely affect the business, financial condition, or results of operations.

Related Party Transactions

• In January and March 2025, Heartflow issued $98.3 million in 2025 Convertible Notes to various investors, including related parties such as Hayfin HeartFlow UK Limited ($23.0 million), BCLS Fund III Investments, LP ($6.59 million), Capricorn Entities ($2.08 million), Timothy C. Barabe ($2.0 million), Lonnie M. Smith ($1.82 million), HCPCIV 1, LLC ($1.46 million), U.S. Venture Partners Funds ($0.81 million), Casey M. Tansey ($0.25 million), and Vikram Verghese ($0.14 million).
• On January 24, 2025, Hayfin converted $23.0 million of outstanding indebtedness under the 2024 Term Loan to 2025 Convertible Notes, making Hayfin a holder of 5% or more of Heartflow's capital stock.
• Warrants to purchase an aggregate of 1,647,667 shares of common stock at an exercise price of $0.03 per share were issued to Hayfin in connection with prior credit agreements.
• In March 2023, Heartflow issued Series F and Series F-1 redeemable convertible preferred stock for $174.9 million cash and $41.0 million from conversion of 2022 Convertible Notes. Related party purchasers included BCLS Fund III Investments, LP ($100.0 million), The Lonnie and Cheryl Smith Family Trust ($15.4 million), Hayfin HeartFlow UK Limited ($15.1 million), HCPCIV 1, LLC ($13.7 million), Wellington Entities ($11.9 million), U.S. Venture Partners Funds ($10.0 million), Capricorn Entities ($8.6 million), The Schiehallion Fund Limited ($7.1 million), and William C. Weldon ($0.36 million).
• Heartflow is party to an amended and restated investors rights agreement with purchasers of redeemable convertible preferred stock, including various directors and 5% holders, granting certain registration rights.
• A voting agreement with certain common and preferred stockholders, including various directors and 5% holders, will terminate upon completion of the IPO.
• An amended and restated right of first refusal and co-sale agreement with certain securityholders will terminate upon completion of the IPO.
• Management rights letters with Wellington Entities, U.S. Venture Partners X, L.P., and Baillie Gifford Funds, granting certain management rights, will terminate upon IPO completion, though some obligations remain.
• A letter agreement with BCLS Fund III Investments, LP granted a board observer right, which will terminate upon IPO completion, but certain lock-up release rights remain.
• A letter agreement with Capricorn Entities granted a board observer right, which will terminate upon IPO completion.
• On March 29, 2023, Heartflow repurchased 102,739 shares of common stock from the Taylor Family Revocable Trust (affiliated with director Charles A. Taylor, Jr., Ph.D.) for $855,150.00.
• Michael Smith, a relative of director Lonnie M. Smith, has been a non-executive employee since 2014, with cash compensation not exceeding $300,000 annually and limited equity compensation.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the IPO. Existing stockholders and management will retain significant control. No dividends are expected in the foreseeable future, making investment returns dependent on stock price appreciation.
• Employees: Benefit from equity incentive plans (2025 Performance Incentive Plan, 2025 Employee Stock Purchase Plan) and a senior leadership severance policy. The company's growth strategy includes hiring additional personnel.
• Customers (Healthcare Providers): Benefit from more accurate, efficient, and clinically useful diagnostic tools for CAD, improved workflow, and enhanced interventional treatment planning. The cloud-based platform is simple to implement and does not require capital equipment purchases.
• Patients: Receive more accurate non-invasive CAD diagnoses, personalized care, reduced unnecessary invasive procedures, lower radiation exposure, and a streamlined diagnostic journey, reducing anxiety.
• Payors (Insurance Companies, Government Programs): Benefit from superior economic efficiency due to reduced unnecessary invasive procedures and more informed treatment decisions, potentially leading to cost savings. Reimbursement policies are critical for product adoption.

Next Steps

• Broaden market education efforts for Heartflow Plaque Analysis as payor coverage increases.
• Launch Heartflow PCI Planner in 2026 as an integrated feature to enhance procedural efficiency.
• Continue to invest in additional clinical evidence to support adoption and expand indications for the Heartflow Platform, including for asymptomatic risk prediction.
• Extend technology leadership through ongoing research and development initiatives focused on improving AI algorithms, optimizing clinical utility, enhancing ease of use, and expanding platform applications.
• Selectively expand geographic footprint by strengthening presence in existing international markets (UK, EU, Australia, Canada, Japan, Israel, Saudi Arabia, UAE, Bahrain) and entering new ones.
• Enroll approximately 20,000 patients across over 30 sites in the U.S. for the DECIDE registry to demonstrate the impact of Heartflow Plaque Analysis on physician decision-making.
• Comply with the Quality Management System Regulation Final Rule (QMSR) effective February 2, 2026.
• Implement a compensation program for non-employee directors consisting of annual retainer fees and long-term equity awards upon Nasdaq listing.
• Adopt a senior leadership severance policy covering executive officers upon completion of the offering.
• File an amended and restated certificate of incorporation and bylaws upon completion of the offering.
• Terminate the 2009 Equity Incentive Plan effective immediately prior to the IPO, with the 2025 Performance Incentive Plan and 2025 Employee Stock Purchase Plan becoming effective upon Nasdaq listing.

Key Dates

Keywords

Coronary Artery Disease, CAD, AI, Artificial Intelligence, Medical Technology, Diagnostics, CCTA, FFRCT, Plaque Analysis, PCI Planner, IPO, Healthcare, Cardiology, MedTech, SEC Filing